Quarterly ResultApr 30, 2026, 04:22 PM
PCRX Q1 Revenue $177.4M, Net Income $2.9M; Treasury Stock Buyback
AI Summary
Pacira BioSciences, Inc. reported Q1 2026 total revenues of $177.4 million, an increase from $168.9 million in Q1 2025. However, net income decreased to $2.9 million ($0.07 EPS) from $4.8 million ($0.10 EPS) in the prior year period. The company also engaged in significant financing activities, including a $50.0 million treasury stock buyback and a $5.0 million repayment of its Revolving Credit Facility.
Key Highlights
- Total revenues increased to $177.4 million in Q1 2026 from $168.9 million in Q1 2025.
- Net income decreased to $2.9 million in Q1 2026 from $4.8 million in Q1 2025.
- Basic and diluted EPS was $0.07 in Q1 2026, down from $0.10 in Q1 2025.
- Purchased $50.0 million in treasury stock during Q1 2026.
- Repaid $5.0 million on the Revolving Credit Facility in Q1 2026.
- EXPAREL net product sales rose to $143.3 million from $136.5 million year-over-year.
- ZILRETTA net product sales increased to $26.8 million from $23.3 million year-over-year.
- Net cash provided by operating activities was $25.7 million, down from $35.5 million.
Price Impact
More from PCRX